FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Equities researchers at HC Wainwright reduced their FY2024 earnings per share estimates for shares of PolyPid in a note issued to investors on Monday, December 16th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($4.83) for the year, down from their previous forecast of ($4.39). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($2.41) EPS.

Separately, Craig Hallum initiated coverage on shares of PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 price target for the company.

PolyPid Trading Up 14.8 %

Shares of NASDAQ:PYPD traded up $0.37 during trading on Thursday, reaching $2.87. 19,086 shares of the company traded hands, compared to its average volume of 8,255. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. PolyPid has a 52-week low of $2.37 and a 52-week high of $9.20. The firm has a market capitalization of $13.77 million, a price-to-earnings ratio of -0.37 and a beta of 1.33. The business’s fifty day moving average is $3.29 and its 200-day moving average is $3.57.

Institutional Investors Weigh In On PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Stonepine Capital Management LLC bought a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned approximately 2.89% of PolyPid at the end of the most recent quarter. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.